LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups

Dupilumab Efficacy in Patients with Eosinophils ≥500 cells/µL or Moderate-to-Severe Allergic Asthma

1. Rabe KF, et al. Eur Respir J. 2022;59(6):2102577     
2. Corren J, et al. J Allergy Clin Immunol Pract. 2020;8(2):516–526

Patients with baseline EOS ≥500 cells/µL (n=436/1902)^1,a

Patients with allergic asthma^c (n=1083/1902)^2,a

Dupilumab significantly reduced the rate of severe exacerbations, improved FEV₁, and demonstrated clinically meaningful improvements in asthma control during the 52-week treatment period in patients with elevated EOS and in patients with moderate-to-severe allergic asthma^d,1,2 

These materials are presented by Sanofi and Regeneron Medical for scientific exchange purposes only. Please refer to the package insert for full SmPC. Sanofi will not foster the application of our medicinal products in a way outside of the approved indication. Please always refer to the SmPC approved in your country before prescribing Dupilumab. 
*Week 12 was the earliest timepoint assessed. ^aPlease see manuscript for full details. ^bHigher scores indicate less asthma control.^cAllergic asthma patients defined as total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline.^dResults should be interpreted with caution as this was a post hoc analysis. 
ACQ-5, 5-item Asthma Control Questionnaire; EOS, eosinophil; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; ppb, parts per billion; Pre-BD FEV₁, pre bronchodilator forced expiratory volume in 1 second; q2w, every 2 weeks; SE, standard error; SmPC, Summary of Product Characteristics.